Navigation Links
OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
Date:8/13/2009

samples after treatment allows us to demonstrate inhibition of Hsp27 expression at the cellular level in the tumor," said Scott Cormack, President and Chief Executive Officer of OncoGenex.

"By conducting this trial through an investigator-sponsored trial with leading clinical researchers at the Vancouver Prostate Centre allows us to advance the development of OGX-427 without a significant commitment of our financial resources," Cormack added.

In preclinical studies conducted by the Vancouver Prostate Centre, OGX-427 had single-agent activity in multiple cancers. In preclinical models of bladder cancer, the investigators observed that bladder cancer tumors were significantly smaller six weeks after OGX-427 administration compared to the control group.

About OGX-427

OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms.

OGX-427 is being evaluated in another Phase 1 clinical trial for the systemic (intravenous) treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. OncoGenex Pharmaceuticals, Inc. recently announced preliminary results of this Phase 1 trial presented during an oral presentation at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. Results as of May 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, after treatment with OGX-427 patients experienced declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

Similar to OGX-011, OGX-427 has potential as a treatment in a broad number o
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Decision Resources, one of the world,s ... healthcare issues, finds that the cost of Roche/Chugai,s ... side-effect profile, are cited most frequently by surveyed ... Avastin for non-small-cell lung cancer treatment in Germany, ... The new Special European Physician & Payer Forum ...
(Date:12/17/2009)... MedX Limited, the manufacturer and global distributor of ... subsidiary of WellTek Incorporated (OTC Bulletin Board: WTKN), ... exercise and medical machines to ... India, Scotland, South Korea, Spain and Switzerland. ... be used in various medical rehabilitation and fitness ...
(Date:12/17/2009)... Inc., (OTC Bulletin Board: SCIE) disclosed today that its ... letter to shareholders: ,, As the end of the ... the recent closing of a $4.3 million round of ... ramping our business performance as we head into 2010. ... force. We are increasing our sales and marketing activities ...
Breaking Medicine Technology:Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 2Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 3WellTek Subsidiary MedX Limited Increases Presence in Global Market 2WellTek Subsidiary MedX Limited Increases Presence in Global Market 3WellTek Subsidiary MedX Limited Increases Presence in Global Market 4SpectraScience Releases Shareholder Newsletter 2SpectraScience Releases Shareholder Newsletter 3SpectraScience Releases Shareholder Newsletter 4SpectraScience Releases Shareholder Newsletter 5Chinese Scientists Develop Database on the Liver 61322 1Elsevier pilots new research tool Reflect in its premier life science journal Cell 10722 1Elsevier pilots new research tool Reflect in its premier life science journal Cell 10722 2Many Kids Feel Threatened in the Classroom 61317 1Many Kids Feel Threatened in the Classroom 61317 2
(Date:12/17/2009)... the particle might someday ease accompanying lung infections , , ... severe pneumonia when infected with the swine flu virus, ... why. , A key to the severity of the ... (TH17), which helps the immune system fight off germs ... in swine-flu patients at 10 Spanish hospitals last summer ...
(Date:12/17/2009)... to announce its newly redesigned Web site: www.psanj.com . PSANJ ... Area often featured in publications such as New York magazine and ... ... December 17, 2009 -- Plastic Surgery Arts of New Jersey (PSANJ) ... . PSANJ is a leading cosmetic surgery center in the New ...
(Date:12/17/2009)... ,for the R&D Informatics Industry, , ... ... Institute is pleased to announce the participation of seven world ... Systems conference to be held on February 3-5, 2010 at ... meeting has been integrated in the Informatics Channel at CHI,s ...
(Date:12/17/2009)... hired Deirdre Byrne to lead the firm’s Interim Leadership division as ... experience in healthcare consulting, Byrne will assume her duties at B. ... ... 17, 2009 -- B. E. Smith recently hired Deirdre ... president. A seasoned executive with nearly 20 years of experience in ...
(Date:12/17/2009)... customary for the holidays to wreak havoc on healthy ... workouts often get short-changed and nutrition is left to ... Waters, it is not impossible to enjoy the holidays ... Raisins and Waters have teamed up to offer advice ... season and get a jump start on New Year,s ...
Breaking Medicine News(10 mins):Health News:Plastic Surgery Arts of New Jersey (PSANJ) Launches New Web Site 2Health News:Plastic Surgery Arts of New Jersey (PSANJ) Launches New Web Site 3Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 3Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3Health News:Celebrity Fitness Trainer Valerie Waters and California Raisins Offer Advice on How to Jump Start the New You in the New Year 2Health News:Celebrity Fitness Trainer Valerie Waters and California Raisins Offer Advice on How to Jump Start the New You in the New Year 3
... objectives in 30 states, particularly in the areas of ... The state of the economy did not deter ... million in grants at its fourth-quarter board meeting in ... in grants for 2008 as a whole, the most ...
... Medical Center has been verified as a Level I Trauma Center-Pediatric by ... , ... Washington, DC (Vocus) February 11, 2009 -- Children,s National Medical ... the Committee on Trauma of the American College of Surgeons (ACS). Children,s ...
... to Be Held at 9:00 A.M. - EXTON, Pa., ... fourth quarter and year end financial results for 2008 are ... the open of the U.S. financial markets.The company will host ... Eastern Time on the same day. During the conference ...
... recent study conducted by researchers at Wake Forest University ... abilities drop as average blood sugar levels rise in ... in this month,s issue of Diabetes Care . ... sub-study of the Action to Control Cardiovascular Risk in ...
... 11 Mesa Laboratories, Inc. (Nasdaq: ... Directors has declared a regular quarterly cash dividend ... payable on March 16, 2009 to shareholders of ... 27, 2009.Mesa Laboratories develops, acquires, manufactures and markets ...
... Emageon Inc. (Nasdaq:, EMAG ), a leader ... health care networks, announced today that it has ... Board: HSSO) that it does not,expect that Stanford ... to consummate the parties, merger transaction today. ...
Other Medicine News:Health News:Kresge Foundation Meets Economic Downturn Head on, Awarding a Record $63.6 Million in Grants in Fourth Quarter 2008 2Health News:Kresge Foundation Meets Economic Downturn Head on, Awarding a Record $63.6 Million in Grants in Fourth Quarter 2008 3Health News:Kresge Foundation Meets Economic Downturn Head on, Awarding a Record $63.6 Million in Grants in Fourth Quarter 2008 4Health News:Kresge Foundation Meets Economic Downturn Head on, Awarding a Record $63.6 Million in Grants in Fourth Quarter 2008 5Health News:Kresge Foundation Meets Economic Downturn Head on, Awarding a Record $63.6 Million in Grants in Fourth Quarter 2008 6Health News:Kresge Foundation Meets Economic Downturn Head on, Awarding a Record $63.6 Million in Grants in Fourth Quarter 2008 7Health News:Kresge Foundation Meets Economic Downturn Head on, Awarding a Record $63.6 Million in Grants in Fourth Quarter 2008 8Health News:Kresge Foundation Meets Economic Downturn Head on, Awarding a Record $63.6 Million in Grants in Fourth Quarter 2008 9Health News:Kresge Foundation Meets Economic Downturn Head on, Awarding a Record $63.6 Million in Grants in Fourth Quarter 2008 10Health News:Children's National Medical Center Trauma Center Receives Highest Verification from American College of Surgeons 2Health News:ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009 2Health News:Higher blood sugar levels linked to lower brain function in diabetics, study shows 2Health News:Emageon Provides Update Regarding Merger Transaction 2Health News:Emageon Provides Update Regarding Merger Transaction 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: